Bora Pharmaceuticals Co., Ltd. (TPE:6472)

Bora Pharmaceuticals Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	18,536	19,014	17,427	14,200	10,494	4,900
Revenue Growth	-2.69%	9.11%	22.72%	35.31%	114.18%	172.28%
Gross Profit Gross Profit Growth	7,406	7,853	7,791	6,991	2,913	1,672
Operating Income Operating Income Growth	3,019	3,294	3,708	5,249	1,922	1,046
Net Income Net Income Growth	1,608	2,981	3,853	3,030	1,392	749.74
Earnings Per Share EPS Growth	8.35	15.81	27.29	24.50	11.78	6.42
EPS Growth	-73.78%	-42.08%	11.42%	107.94%	83.40%	28.53%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Adjustments and Eliminations Adjustments and Eliminations Growth	-5,879	-5,437	-5,606	-761.19	-304	-135.84
Other Operations Department Other Operations Department Growth	1,026	845.31	802.33	273.38	202.85	85.09
CDMO Operations Department CDMO Operations Department Growth	8,770	8,838	6,920	5,437	4,835	4,418
Sales Operations Department Sales Operations Department Growth	14,619	14,768	15,310	9,251	5,761	532.39
Total Total Growth	18,536	19,014	17,427	14,200	10,494	4,900

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	4,888	5,136	5,917	3,396	3,529	910.75
Total Debt Total Debt Growth	17,547	18,227	18,973	4,991	7,596	2,219
Net Cash (Debt) Net Cash Growth	-12,659	-13,091	-13,056	-1,595	-4,067	-1,308
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-67.51	-69.41	-92.49	-12.84	-34.34	-11.20

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	3,775	4,504	980.02	4,614	2,010	1,237
Capital Expenditures CapEx Growth	-1,017	-928.67	-528.1	-297.71	-194.81	-163.48
Free Cash Flow Free Cash Flow Growth	2,758	3,575	451.92	4,316	1,815	1,073
Free Cash Flow Growth	422.44%	691.04%	-89.53%	137.76%	69.15%	3657.55%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	39.96%	41.30%	44.70%	49.23%	27.76%	34.12%
Operating Margin	16.29%	17.32%	21.28%	36.97%	18.32%	21.35%
Pretax Margin	13.39%	27.76%	29.97%	28.62%	17.53%	20.90%
Profit Margin	8.67%	15.68%	22.11%	21.34%	13.26%	15.30%
FCF Margin	14.88%	18.80%	2.59%	30.39%	17.30%	21.90%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	10.000	10.000	11.669	10.002	5.133	2.041
Dividend Per Share Growth	-14.30%	-14.30%	16.67%	94.84%	151.53%	118.14%
Dividend Yield	2.64%	2.05%	1.90%	1.94%	2.01%	2.01%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	43.23	20.30	20.17	21.32	22.36	16.60
Forward PE	13.97	11.87	16.07	21.03	11.57	14.97
P/FCF Ratio	17.46	16.93	171.96	14.97	17.14	11.60
PS Ratio	2.60	3.18	4.46	4.55	2.97	2.54

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error